エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 27, 2025
KYMERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39460 | 81-2992166 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
Kymera Therapeutics, Inc.
| 500 North Beacon Street, 4th Floor |
| Watertown, Massachusetts 02472 |
| (Address of principal executive offices, including zip code) |
(857) 285-5300
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trade |
Name of each exchange |
||
| Common Stock, $0.0001 par value per share | KYMR | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 27, 2025, Ellen Chiniara, J.D., Chief Legal Officer of Kymera Therapeutics, Inc. (the “Company”), informed the Company of her intent to retire from the role of Chief Legal Officer, effective September 3, 2025. Ms. Chiniara’s retirement and departure from the Company was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Ms. Chiniara will not receive any severance payments or benefits in connection with her departure. The Company thanks Ms. Chiniara for her years of service as Chief Legal Officer.
Effective September 3, 2025, Brian R. Adams, J.D., will succeed Ms. Chiniara as Chief Legal Officer of the Company.
Item 7.01. Regulation FD Disclosure.
On September 3, 2025, the Company issued a press release announcing the retirement of Ms. Chiniara and the appointment of Mr. Adams as the Company’s Chief Legal Officer. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release issued by Kymera Therapeutics, Inc. dated September 3, 2025. | |
| 104 | Cover Page lnteractive Data File (embedded within the Inline XBRL document). | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Kymera Therapeutics, Inc. | ||||||
| Date: September 3, 2025 | By: | /s/ Nello Mainolfi |
||||
| Nello Mainolfi | ||||||
| President and Chief Executive Officer | ||||||
Exhibit 99.1
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
Watertown, Mass. (September 3, 2025) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He will lead Kymera’s legal, governance, and intellectual property functions. Mr. Adams will succeed Ellen Chiniara who is retiring from her role to focus on board service, mentoring and other advisory opportunities.
“Kymera is building a fully integrated global medicines company focused on transforming care for millions of patients living with immuno-inflammatory diseases through our portfolio of first-in-class oral medicines with biologics-like profiles,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “We’re thrilled to welcome Brian to our team. His proven leadership and deep expertise will be instrumental as we advance and scale our novel programs through clinical development and toward commercialization. Additionally, we would like to sincerely thank Ellen for her strong dedication and many contributions to Kymera’s success throughout the company’s remarkable growth and wish her the best as she pursues her next chapter.”
“I was drawn to Kymera by its unwavering commitment to long-term scientific innovation and meaningful clinical impact,” said Mr. Adams. “I am thrilled to be joining the company at such an exciting time of progress and look forward to working with this pioneering team as we strive to redefine what’s possible in immunology with groundbreaking oral medicines.”
Before joining Kymera, Mr. Adams was Chief Legal Officer of Relay Therapeutics, responsible for leading all aspects of Relay’s legal and compliance operations. Prior to Relay, he served as Senior Vice President, General Counsel and Secretary at Keryx Biopharmaceuticals. Earlier in his career, he held senior roles at Algeta ASA, AVEO Oncology, and Genzyme Corporation. Additionally, he practiced at Bingham McCutchen LLP, where he advised private equity sponsors, biotechs, and other emerging technology companies on a broad range of corporate matters and financing transactions. Mr. Adams holds a B.A. from Harvard University and a J.D. from the Catholic University of America’s Columbus School of Law.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Availability of Other Information About Kymera Therapeutics
For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300